Literature DB >> 35641096

Epidermal clearance of Candida albicans is mediated by IL-17 but independent of fungal innate immune receptors.

Mari T Iwasawa1, Hideaki Miyachi1, Seiichiro Wakabayashi1, Takashi Sugihira2, Reika Aoyama2, Seitaro Nakagawa1, Yuki Katayama1, Mitsutoshi Yoneyama3, Hiromitsu Hara4, Yoichiro Iwakura3,5,6, Masanori Matsumoto7,8, Naohiro Inohara7,8, Hanako Koguchi-Yoshioka2, Manabu Fujimoto2,9, Gabriel Núñez7,8, Hiroyuki Matsue1, Yuumi Nakamura1,2,9, Shinobu Saijo3.   

Abstract

IL-17 plays important roles in host defense against Candida albicans at barrier surfaces and during invasive infection. However, the role of IL-17 in host defense after colonization of the epidermis, a main site of C. albicans infection, remains poorly understood. Using a murine model of epicutaneous candidiasis without skin abrasion, we found that skin inflammation triggered by epidermal C. albicans colonization was self-limiting with fungal clearance completed by day 7 after inoculation in wild-type mice or animals deficient in IL-17A or IL-17F. In contrast, marked neutrophilic inflammation in the epidermis and impaired fungal clearance were observed in mice lacking both IL-17A and IL-17F. Clearance of C. albicans was independent of Dectin-1, Dectin-2, CARD9 (caspase-recruitment domain family, member 9), TLR2 (Toll-like receptor 2) and MyD88 in the epidermal colonization model. We found that group 3 innate lymphoid cells (ILC3s) and γδT cells were the major IL-17 producers in the epicutaneous candidiasis model. Analyses of Rag2-/- mice and Rag2-/-Il2rg-/- mice revealed that production of IL-17A and IL-17F by ILC3s was sufficient for C. albicans clearance. Finally, we found that depletion of neutrophils impaired C. albicans clearance in the epidermal colonization model. Taken together, these findings indicate a critical and redundant function of IL-17A and IL-17F produced by ILC3s in host defense against C. albicans in the epidermis. The results also suggest that epidermal C. albicans clearance is independent of innate immune receptors or that these receptors act redundantly in fungal recognition and clearance. Published by Oxford University Press on behalf of The Japanese Society for Immunology 2022.

Entities:  

Keywords:  epicutaneous candidiasis; innate immune receptors

Mesh:

Substances:

Year:  2022        PMID: 35641096      PMCID: PMC9317997          DOI: 10.1093/intimm/dxac019

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   5.071


  56 in total

Review 1.  IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans.

Authors:  Heather R Conti; Sarah L Gaffen
Journal:  J Immunol       Date:  2015-08-01       Impact factor: 5.422

2.  Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.

Authors:  Natasha Whibley; Elaine Tritto; Elisabetta Traggiai; Frank Kolbinger; Pierre Moulin; Dominique Brees; Bianca M Coleman; Anna J Mamo; Abhishek V Garg; Jillian R Jaycox; Ulrich Siebenlist; Michael Kammüller; Sarah L Gaffen
Journal:  J Leukoc Biol       Date:  2016-01-04       Impact factor: 4.962

3.  An IL-17F.S65L Knock-In Mouse Reveals Similarities and Differences in IL-17F Function in Oral Candidiasis: A New Tool to Understand IL-17F.

Authors:  Chunsheng Zhou; Leticia Monin; Rachael Gordon; Felix E Y Aggor; Rami Bechara; Tara N Edwards; Daniel H Kaplan; Sebastien Gingras; Sarah L Gaffen
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

4.  Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans.

Authors:  Shinobu Saijo; Noriyuki Fujikado; Takahisa Furuta; Soo-hyun Chung; Hayato Kotaki; Keisuke Seki; Katsuko Sudo; Shizuo Akira; Yoshiyuki Adachi; Naohito Ohno; Takeshi Kinjo; Kiwamu Nakamura; Kazuyoshi Kawakami; Yoichiro Iwakura
Journal:  Nat Immunol       Date:  2006-12-10       Impact factor: 25.606

5.  Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells.

Authors:  Kenji Kabashima; Daiji Sakata; Miyako Nagamachi; Yoshiki Miyachi; Kayo Inaba; Shuh Narumiya
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

Review 6.  Candida albicans-epithelial interactions and induction of mucosal innate immunity.

Authors:  Julian R Naglik; Annika König; Bernhard Hube; Sarah L Gaffen
Journal:  Curr Opin Microbiol       Date:  2017-11-17       Impact factor: 7.934

Review 7.  Nosocomial fungal infections: epidemiology, diagnosis, and treatment.

Authors:  Joshua Perlroth; Bryan Choi; Brad Spellberg
Journal:  Med Mycol       Date:  2007-06       Impact factor: 4.076

8.  Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.

Authors:  Timothy J Break; Vasileios Oikonomou; Nicolas Dutzan; Jigar V Desai; Marc Swidergall; Tilo Freiwald; Daniel Chauss; Oliver J Harrison; Julie Alejo; Drake W Williams; Stefania Pittaluga; Chyi-Chia R Lee; Nicolas Bouladoux; Muthulekha Swamydas; Kevin W Hoffman; Teresa Greenwell-Wild; Vincent M Bruno; Lindsey B Rosen; Wint Lwin; Andy Renteria; Sergio M Pontejo; John P Shannon; Ian A Myles; Peter Olbrich; Elise M N Ferré; Monica Schmitt; Daniel Martin; Daniel L Barber; Norma V Solis; Luigi D Notarangelo; David V Serreze; Mitsuru Matsumoto; Heather D Hickman; Philip M Murphy; Mark S Anderson; Jean K Lim; Steven M Holland; Scott G Filler; Behdad Afzali; Yasmine Belkaid; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

9.  IL-1 receptor antagonist-deficient mice develop autoimmune arthritis due to intrinsic activation of IL-17-producing CCR2(+)Vγ6(+)γδ T cells.

Authors:  Aoi Akitsu; Harumichi Ishigame; Shigeru Kakuta; Soo-Hyun Chung; Satoshi Ikeda; Kenji Shimizu; Sachiko Kubo; Yang Liu; Masayuki Umemura; Goro Matsuzaki; Yasunobu Yoshikai; Shinobu Saijo; Yoichiro Iwakura
Journal:  Nat Commun       Date:  2015-06-25       Impact factor: 14.919

10.  Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow.

Authors:  Z Hao; K Rajewsky
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.